News

Although there are now more treatment options available for non-motor symptoms in Parkinson’s disease, a lack of evidence on their effectiveness and safety means that more studies and new therapeutic strategies are needed, according to a review study. The study, “Update on Treatments for Nonmotor Symptoms…

The United States Patent and Trademark Office (USPTO) has approved a patent covering the composition and method of administration of a new levodopa replacement formulation for treating Parkinson’s disease. Lecigon was developed by Lobsor Pharmaceuticals to be the next-generation of Stalevo (marketed by Novartis), a widely used…

Parkinson’s disease (PD) could be identified through a noninvasive analysis of chemical components of sebum, the oily substance that helps keep skin and hair moisturized, a pilot study suggests. The study, “Discovery of Volatile Biomarkers of Parkinson’s Disease from Sebum,” was published in the journal ACS…

With the goal of advancing Parkinson’s disease (PD) diagnosis and therapy by securely and safely sharing patient-produced data, the healthcare artificial intelligence (AI) company ConnectedLife is partnering with the technology platform Ocean Protocol. The collaboration marries the Internet of Things (IoT) — connected devices able to communicate…

As it sometimes happens in rare-disease research, a prospective therapy for one disorder has potential to help another. So it is that, at Temple University, molecular pharmacologist Marlene Jacobson, PhD, has been awarded a joint grant to explore how a discovery could affect Parkinson’s disease (PD) patients. Specifically,…

Mild cognitive impairment, motor and olfactory deficits, and erectile dysfunction are among the markers able to predict the development of Parkinson’s and associated disorders in people with rapid eye movement sleep behavior disorder, according to a large study. The research was published in the article, “Risk…

ProMIS Neurosciences will present evidence of the selectivity of several of its antibody candidates to target the toxic forms of alpha-synuclein, a key component of Lewy bodies that underlie the development of Parkinson’s disease. Neil Cashman, PhD, chief scientific officer of ProMIS, will present the study, “Targeting of Pathogenic Aggregated…

Hydrotherapy may provide significant balance and mobility benefits in patients with Parkinson’s disease compared to medication and land-based exercises, according to a review study. The research, “The Effects of Hydrotherapy on Balance, Functional Mobility, Motor Status, and Quality of Life in Patients with Parkinson Disease: A Systematic…

Exercise and fall prevention education can improve front-to-back trunk mobility in Parkinson’s patients with a history of falls, according to a Phase 2 clinical trial. The study, “Trunk exercises improve gait symmetry in Parkinson disease: A blind phase II randomized-controlled trial” was published in the American Journal of…

Alpha-synuclein reduces the levels and impairs the function of ATP-dependent Clp protease (ClpP), an enzyme found in mitochondria — the cell compartments responsible for the production of energy — causing mitochondrial damage and oxidative stress, a study shows. The study, “Alpha-synuclein suppresses mitochondrial protease ClpP to trigger mitochondrial oxidative…